Live
FierceBiotechAlumis pulls back from would-be rival to Amgen’s Tepezza after assessing prospectsEndpoints NewsSupreme Court preserves mail access for abortion pillFierceBiotechAardvark to dig into phase 3 data early after FDA imposes holdSiemens HealthineersSiemens Healthineers Wins Key US Clearances As Valuation Gap Widens - simplywall.stBioNTechBioNTech’s Clinical and Corporate Overhaul: Cancer Data Improves as COVID Era Ends - AD HOC NEWSEvery GreenBiotech Just Hit Fast Forward. Is Europe’s Seed Sector Ready? - seedworld.comIQVIAIQVIA And Kexing Biopharm Advance Global Biosimilar Expansion Through AI Enabled Strategic Collaboration - BioPharma APACIlluminaCorvex Funds tied to Illumina (NASDAQ: ILMN) sell shares and partly unwind equity swaps - Stock TitanFierceBiotechChutes & Ladders—AC Immune CEO bids adieuEli LillyIs Eli Lilly Going To $1,100? - 24/7 Wall St.Clinical OMICsAI in Healthcare: Symposium InsightsFierceBiotechSignant Health buys Ametris to unite data streams in clinical trials
This story is not available in the archive.